Free Trial

Zhengye Biotechnology (ZYBT) Competitors

Zhengye Biotechnology logo
$5.55 0.00 (0.00%)
As of 07/25/2025 04:00 PM Eastern

ZYBT vs. ELVN, AVDL, ARDX, DYN, GPCR, BGM, GHRS, AKBA, SANA, and AMPH

Should you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), BGM Group (BGM), GH Research (GHRS), Akebia Therapeutics (AKBA), Sana Biotechnology (SANA), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.

Zhengye Biotechnology vs. Its Competitors

Zhengye Biotechnology (NASDAQ:ZYBT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Zhengye Biotechnology's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Enliven Therapeutics N/A -31.84%-30.09%

Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 94.34%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zhengye Biotechnology has higher revenue and earnings than Enliven Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$25.53M10.25$1.55MN/AN/A
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.04

In the previous week, Enliven Therapeutics had 7 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.87 beat Enliven Therapeutics' score of 0.51 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
Zhengye Biotechnology Very Positive
Enliven Therapeutics Positive

95.1% of Enliven Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Enliven Therapeutics beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYBT vs. The Competition

MetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$261.77M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E RatioN/A21.3228.3920.08
Price / Sales10.25280.80430.0899.95
Price / Cash53.8642.7636.2258.56
Price / Book5.448.378.675.88
Net Income$1.55M-$55.19M$3.25B$258.89M
7 Day Performance-2.46%5.86%4.30%3.70%
1 Month Performance-21.28%17.29%10.57%11.71%
1 Year PerformanceN/A4.39%35.68%17.98%

Zhengye Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYBT
Zhengye Biotechnology
N/A$5.55
flat
N/AN/A$261.77M$25.53M0.00278Positive News
Gap Up
ELVN
Enliven Therapeutics
2.6179 of 5 stars
$21.56
-1.4%
$41.20
+91.1%
-15.3%$1.07BN/A-11.2350Insider Trade
Gap Up
AVDL
Avadel Pharmaceuticals
2.0935 of 5 stars
$11.23
+2.3%
$18.33
+63.3%
-32.3%$1.06B$169.12M-41.5970
ARDX
Ardelyx
4.1115 of 5 stars
$4.43
+0.2%
$10.89
+145.8%
-21.9%$1.06B$333.61M-20.1490
DYN
Dyne Therapeutics
3.8174 of 5 stars
$9.21
+0.4%
$40.63
+341.1%
-76.7%$1.04BN/A-2.57100
GPCR
Structure Therapeutics
2.9261 of 5 stars
$18.19
+0.3%
$76.17
+318.7%
-53.2%$1.04BN/A-20.91136Positive News
BGM
BGM Group
N/A$10.04
-5.6%
N/AN/A$1.03B$25.10M0.00298High Trading Volume
GHRS
GH Research
2.1102 of 5 stars
$16.69
-14.4%
$32.00
+91.7%
+22.8%$1.01BN/A-21.1310
AKBA
Akebia Therapeutics
3.7957 of 5 stars
$3.85
+0.3%
$6.75
+75.3%
+140.5%$1.01B$160.18M-18.33430Positive News
SANA
Sana Biotechnology
3.1717 of 5 stars
$4.87
+9.7%
$9.17
+88.2%
-18.2%$1.00BN/A-5.53380
AMPH
Amphastar Pharmaceuticals
4.4131 of 5 stars
$21.35
+0.8%
$32.33
+51.4%
-46.9%$998.88M$731.97M7.742,028

Related Companies and Tools


This page (NASDAQ:ZYBT) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners